A Phase I/II Study to Evaluate the Safety and efficacy of Liposomes Encapsulating Paclitaxel (EndoTAG-1 [ET]) in Patients with Refractory, Nonresectable Head and Neck Squamous Cell Carcinoma.

Trial Profile

A Phase I/II Study to Evaluate the Safety and efficacy of Liposomes Encapsulating Paclitaxel (EndoTAG-1 [ET]) in Patients with Refractory, Nonresectable Head and Neck Squamous Cell Carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2015

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top